Ogkologos | Ogkologos.com | Page 82

Home Authors Posts by Ogkologos

4396 POSTS 0 COMMENTS

Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient...

Ogkologos - May 31, 2024

World No Tobacco Day 2024: European Societies call for an EU...

Ogkologos - May 30, 2024

Tovorafenib Approved for Some Children with Low-Grade Glioma

Ogkologos - May 28, 2024

Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced...

Ogkologos - May 28, 2024

Adding 24 Months of ADT Improves Metastasis-Free Survival in Patients with...

Ogkologos - May 27, 2024

FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell...

Ogkologos - May 24, 2024

Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical...

Ogkologos - May 24, 2024

EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of...

Ogkologos - May 23, 2024

Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than...

Ogkologos - May 22, 2024

Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer

Ogkologos - May 21, 2024

1...818283...440 Page 82 of 440

MOST POPULAR

Sacituzumab Govitecan Demonstrates Significant Improvement in PFS in Heavily Pretreated, Locally...

September 5, 2022

20 years of Cancer Research UK: Celebrating our research nurses

December 7, 2022

Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in...

July 4, 2024

European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to...

September 30, 2026

HOT NEWS

Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination...

Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate...

How to select adjuvant endocrine therapy for postmenopausal women with HR-positive...

Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers